Skip to main content
Sign In

Bolin Liu, MD

Associate Professor


  • MD, Beijing Medical University, Beijing, China (1987)
  • MS, Institute of Hematology, Peking Union Medical College (PUMC) and Chinese Academy of Medical Science (CAMS), Tianjin, China (1994)

Postdoctoral Education:

  • Postdoctoral Fellow Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center (UTMDACC), Houston, TX (1998-2001)
  • Visiting Scientist Department of Surgical Oncology, UTMDACC, Houston, TX (1994-1998) 

Research Activities:

  • ErbB receptor tyrosine kinase-mediated cell signaling in breast cancer
  • Epigenetic potentiation of chemotherapy in cancer treatment
  • View Research Page​

Selected Publications:

  • Huang, X.P., Gao, L., Wang, S., McManaman, J.L., Thor, A.D., Yang, X., Esteva, F.J., and Liu, B. Heterotrimerization of the growth factor receptors erbB2, erbB3, and insulin-like growth factor-I receptor in breast cancer cells resistant to Herceptin. Cancer Research 70(3):1204-1214, 2010
  • Lee, C-K., Wang, S., Huang, X., Ryder, J., and Liu, B. HDAC Inhibition Synergistically Enhances Alkylator-induced DNA Damage Responses and Apoptosis in Multiple Myeloma Cells. Cancer Letters 296: 233-240, 2010
  • Wang, S., Huang, X., Lee, C-K., and Liu, B. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin. Oncogene 29: 4225–4236, 2010
  • Huang, X., Wang, S., Lee, C-K., Yang, X., and Liu, B. HDAC inhibitor SNDX-275 enhances efficacy of trastuzumab in erbB2-overexpressing breast cancer cells and exhibits potential to overcome trastuzumab resistance. Cancer Letters 2011 Aug 1;307(1):72-9.​
  • Ma J, Wang S, Zhao M, Deng XS, Lee CK, Yu XD, Liu B. Therapeutic potential of cladribine in combination with STAT3 inhibitor against multiple myeloma. BMC Cancer 2011 Jun 16;11(1):255.
  • Liu, B.*, Fan, Z., Edgerton, S.M., Yang, X., Lind, S.E., and Thor, A.D.* Potent Anti-proliferative Effects of Metformin on Trastuzumab-resistant Breast Cancer Cells via Inhibition of ErbB2/IGF-1 Receptor Interactions. Cell Cycle    Sep 1, 10 (17): 2959-2966, 2011 *Corresponding authors
  • Cai, B., Wang, S., Huang, J., Lee, C-K., Gao, C., and Liu, B. Cladribine and bendamustine exhibit inhibitory activity in dexamethasone-sensitive and -resistant multiple myeloma cells. American Journal of Translational Research 2013; 5(1):36-46.
  • Wang, L., Huang, Z., Lin H., Li, Z., Hetzel, F.W., and Liu, B. Effects of photofrin-mediated photocytotoxicity on a panel of human pancreatic cancer cells. Photodiagnosis and Photodynamic Therapy, 2013  

  • Wang, S., Huang, J., Lyu, H., Lee, C-K., Tan, J., Wang, J., and Liu, B. Functional cooperation of miR-125a, miR-125b, and miR-205 in entinostat-induced downregulation of erbB2/erbB3 and apoptosis in breast cancer cells. Cell Death & Disease (2013) 4, e556; doi:10.1038/cddis.2013.79

  • Cai, B., Lyu, H., Huang, J., Wang, S., Lee, C-K., Gao, C., and Liu, B. Combination of Bendamustine and Entinostat Synergistically Inhibits Proliferation of Multiple Myeloma Cells via Induction of Apoptosis and DNA Damage Response. Cancer Letters 2013; 335 (2): 343-350.

  • Wahdan-Alaswad, R. and Liu, B. “Sister” miRNAs in cancers. Cell Cycle 2013; 12 (24): 3703-3704; December 15, 2013

  • Wang, S., Huang, J., Lyu, H., Cai, B., Yang, X., Li, F., Tan, J., Edgerton, S.M., Thor, A.D., Lee, C-K., and Liu, B. Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer. Breast Cancer Research 2013; 15:R101. doi:10.1186/bcr3563

  • Huang, J., Wang, S., Lyu, H., Cai, B., Yang, X., Wang, J., and Liu, B. The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells. Molecular Cancer 2013; 12:134 doi:10.1186/1476-4598-12-134

  • Wahdan-Alaswad, R., Fan, Z., Edgerton, S.M., Liu, B., Deng, X-S., Arnadottir, S.S., Richer, J.K., Anderson, S.M., and Thor, A.D.  Glucose promotes breast cancer aggression and reduces metformin efficacy. Cell Cycle 12(24): 3759-3769; December 15, 2013

  • Milgroom, A., Intrator, M., Madhavan, K., Mazzaro, L., Shandas, R., Liu, B., and Park, D. Mesoporous silica nanoparticles as a breast-cancer targeting ultrasound contrast agent. Colloids Surf. B: Biointerfaces 2014 Apr 1; 116:652-7

  •  Lee, Y., Ma, J., Lyu, H., Huang, J., Kim, A., and Liu, B. Role of erbB3 receptors in cancer therapeutic resistance. Acta Biochim Biophys Sin 2014, 46: 190–198

  • Ma, J., Lyu, H., Huang, J., and Liu, B. Targeting of erbB3 receptor to overcome resistance in cancer treatment. Molecular Cancer 2014, 13:105

  • Zhu P, Davis M, Blackwelder AJ, Bachman N, Liu B, Edgerton SM, Williams LL, Thor AD, Yang X. Metformin selectively targets tumor-initiating cells in ErbB2-overexpressing breast cancer models. Cancer Prev Res (Phila). 2014; 7(2):199-210